Starbucks Corp. (NASDAQ: SBUX) CEO Brian Niccol has made several poor decisions since he took his job in September.
As Ford Has Another Recall, CEO Farley Needs to Be Fired — Neutral
F 24/7 Wall Street — July 17, 2025Like a Greek chorus, Ford Motor Co. (NYSE: F) management says it will improve its quality problems.
Columbus McKinnon to Host First Quarter Fiscal 2026 Earnings Conference Call on July 30, 2025 — Neutral
CMCO PRNewsWire — July 17, 2025CHARLOTTE, N.C. , July 17, 2025 /PRNewswire/ -- Columbus McKinnon Corporation (Nasdaq: CMCO), a leading designer, manufacturer and marketer of intelligent motion solutions for material handling, will release its first quarter fiscal 2026 results before the market opens on Wednesday, July 30, 2025.
Tevogen Signs Letter of Intent for New In-House Cell Therapy Manufacturing Facility — Neutral
TVGN GlobeNewsWire — July 17, 2025WARREN, N.J., July 17, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN) today announced the signing of a letter of intent to lease a 17,428-square-foot facility in New Jersey. The facility, formerly occupied by Pfizer and Cordis, a previous division of Johnson & Johnson, should support the Company's cell therapy manufacturing operations.
Bit Origin Secures $500 Million Equity and Debt Facilities to Launch Dogecoin Treasury — Neutral
BTOG GlobeNewsWire — July 17, 2025-Much Doge. Such Utility.
Creative Medical Technology Holdings Receives Notice of Allowance for the Prevention and/or Treatment of Type 1 Diabetes Using Modulated Immune Cells — Neutral
CELZ GlobeNewsWire — July 17, 2025PHOENIX, July 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company specializing in regenerative medicine, today announced that it has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a U.S. patent application titled, “Prevention and/or Treatment of Type 1 Diabetes by Augmentation of Myeloid Suppressor Cell Activity.”
Peer-Reviewed Study Validates Renovaro's Genetically Engineered Dendritic Cell Therapy with Potent Anti-Tumor Efficacy — Neutral
RENB Accesswire — July 17, 2025Landmark preclinical data validate Renovaro's platform representing a step forward in the fight against pancreatic and solid tumors LOS ANGELES, CALIFORNIA / ACCESS Newswire / July 17, 2025 / Renovaro Biosciences (NASDAQ:RENB), an oncology and neurology focused TechBio company, today announced the publication of a peer-reviewed study in Vaccines, a leading journal in the field of immunology. The paper details compelling preclinical data on Renovaro's next-generation dendritic cell (DC) therapy platform, showcasing its ability to significantly reduce pancreatic tumor burden and activate robust immune responses in humanized mouse models.
Grid Dynamics Helps SmartRay Create an AI Robotic Inspection Platform in Collaboration with Wandelbots — Neutral
GDYN Business Wire — July 17, 2025SAN RAMON, Calif.--(BUSINESS WIRE)--Grid Dynamics Holdings, Inc. (Nasdaq: GDYN) (Grid Dynamics), a leading provider of technology consulting, platform and product engineering, AI, and digital engagement services, today announced the successful launch of SmartRay's new software platform for robotic weld inspection. Drawing on its deep expertise in robotic control, advanced optimization, and AI engineering, Grid Dynamics helped transform robotic programming workflows at SmartRay—a global leader i.
45 Barron's 2025 Mid-Year Pro-Picks: 3 Ideal July DiviDogs — Positive
AEP AGNC ALL DHR FAF FLMI GDEN JAAA NLY PBI SBGI T TDS TGNA TGT Seeking Alpha — July 17, 2025I analyze Barron's Mid-Year 2025 Roundtable Pro Picks using the yield-based 'dogcatcher' method to identify high-yield, safer dividend stocks. AT&T, Tegna, and Pitney Bowes stand out as 'safer' dividend dogs, with prices below annual dividends from $1,000 invested, signaling attractive entry points. The top ten high-yield picks offer projected 24.3% average net gains by July 2026, with lower-than-market volatility, but some face negative free cash flow margins.
United Airlines CEO Scott Kirby: Seeing an uptick in demand for business travel — Positive
UAL CNBC Television — July 17, 2025CNBC's Phil LeBeau and United Airlines CEO Scott Kirby join 'Squawk Box' to discuss the company's quarterly earnings results, state of air travel demand, Q3 forecast, travel around Newark Liberty International Airport, international travel demand, and more.
Lucid shares surge as Uber invests in robotaxi partnership — Positive
LCID UBER Proactive Investors — July 17, 2025Lucid Group Inc (NASDAQ:LCID) shares leapt 44% in premarket trading on Thursday after a $300 million investment from Uber was announced, with the aim of deploying "20,000 or more" electric robotaxis. Electric vehicles made by the Californian luxury auto challenger will be equipped with Level 4 self-driving software from Nuro and deployed over six years around the world.
Lucid Group (NASDAQ: LCID) stock is up 46.72% in premarket trading on Thursday as of publication time, following Uber Technologies' (NYSE: UBER) announcement of a $300 million investment in the electric vehicle maker as part of a six-year robotaxi partnership.
Company to aggressively advance its treasury strategy Company positioned to become one of the largest public holders of Ethereum FRISCO, Texas , July 17, 2025 /PRNewswire/ -- GameSquare Holdings, Inc. (NASDAQ: GAME), ("GameSquare", or the "Company"), a next-generation media, entertainment, and technology company, today announced the pricing of its previously announced underwritten public offering for the sale of 46,666,667 shares of common stock at a price of $1.50 per share for expected aggregate gross proceeds of approximately $70 million before deducting underwriting discounts and commissions and offering expenses. The Company will use most of the offering proceeds to significantly increase …
Lisata Therapeutics and WARPNINE complete enrollment in iLSTA trial, share encouraging preliminary results — Positive
LSTA Proactive Investors — July 17, 2025Lisata Therapeutics Inc (NASDAQ:LSTA) and WARPNINE announced the completion of patient enrollment in the Phase 1b/2a iLSTA trial, which is evaluating Lisata's therapy candidate certepetide in combination with standard-of-care chemotherapy and immunotherapy in pancreatic cancer. It is evaluating the therapy in patients with locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC), rather than metastatic PDAC.
Fee Income & NII to Drive KeyCorp's Q2 Earnings, Provisions to Hurt — Neutral
KEY Zacks Investment Research — July 17, 2025KEY's Q2 earnings are expected to have been boosted by fee income and NII, but rising provisions are likely to have weighed on it.
Uber just made its robotaxi play — with a big investment in Lucid — Positive
LCID UBER Business Insider — July 17, 2025Uber is investing hundreds of millions into the robotaxi wars. The company partnered with Lucid, which makes the Gravity EVs that Uber will use in its robotaxi fleet.
Swiss pharma giant Novartis bets on a breast cancer blockbuster as sales rise — Positive
NVS CNBC — July 17, 2025Novartis said Thursday that it expects its Kisqali breast cancer treatment to be the next blockbuster drug within its portfolio. The Swiss pharma firm is looking to shift reliance away from its Entresto heart failure therapy.
Globavend Holdings Limited Announces 1-for-200 Reverse Stock Split — Neutral
GVH GlobeNewsWire — July 17, 2025PERTH, AUSTRALIA, July 17, 2025 (GLOBE NEWSWIRE) -- Globavend Holdings Limited (“Globavend” or the “Company”) (NASDAQ: GVH), an emerging e-commerce logistics provider, today announced that it intends to effect a 1-for-200 reverse stock split of the Company's ordinary shares (the “Reverse Stock Split”). The Company anticipates that the ordinary shares will begin trading on the Nasdaq Capital Market on a post-Reverse Stock Split basis upon the opening of the market on July 21, 2025 (the “Effective Date”).
ArcBest Announces Retirement of CEO Judy McReynolds; ArcBest President Seth Runser Named CEO-elect — Neutral
ARCB Business Wire — July 17, 2025FORT SMITH, Ark.--(BUSINESS WIRE)--Judy McReynolds will retire as ArcBest CEO on December 31, 2025. ArcBest President Seth Runser will become the next CEO, effective January 1, 2026.
ASML's Q2 earnings exceeded expectations with strong sales, high gross margins, and robust share buybacks, reinforcing my confidence in the company. Management continues to underpromise and overdeliver, maintaining a conservative outlook while consistently beating their own guidance. Short-term uncertainty for 2026 revenue growth exists due to macroeconomic and geopolitical factors, but long-term 2030 targets remain intact.